ARTICLE | Company News
MorphoSys, Novartis deal to run through 2017
July 7, 2009 1:04 AM UTC
MorphoSys AG (Xetra:MOR) said a clause in a 2007 antibody deal allowing Novartis AG (NYSE:NVS; SIX:NOVN) to terminate the collaboration after seven years was removed because MorphoSys met predetermined technology improvement goals, including the release of its HuCAL Platinum antibody library. The deal will run until 2017, with $600 million in financing committed to MorphoSys (See BioCentury, Dec. 24, 2007). ...